• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于测定普通肝素、低分子肝素、磺达肝癸钠和凝血酶抑制剂抗凝作用的凝血酶原酶诱导凝血时间测定法。

Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.

作者信息

Calatzis Andreas, Peetz Dirk, Haas Sylvia, Spannagl Michael, Rudin Karin, Wilmer Marianne

机构信息

Department of Haemostasis and Transfusion Medicine, Munich University Clinic, Munich, Germany.

出版信息

Am J Clin Pathol. 2008 Sep;130(3):446-54. doi: 10.1309/Q0G21Y26UR0UHQ1A.

DOI:10.1309/Q0G21Y26UR0UHQ1A
PMID:18701419
Abstract

The prothrombinase-induced clotting time assay (PiCT, Pentapharm, Basel, Switzerland) is a clotting assay sensitive to factor Xa and factor IIa inhibitors. It is based on the addition of factor Xa and snake venom RVV-V (Russell viper venom factor V activator) specifically activating factor V and phospholipids to platelet-poor plasma. Following an incubation time, the mixture is recalcified and the clotting time is determined. An almost linear dose-response and high sensitivity of the assay for unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), r-hirudin, and argatroban was found. Fondaparinux showed a nonlinear dose-response. By using ex vivo samples, the following Pearson correlation coefficients were found: r=0.85 between amidolytic anti-Xa and PiCT for 120 LMWH and 24 control samples; r=0.86 between amidolytic anti-Xa activity and PiCT for 68 UFH and 24 control samples; and r=0.94 between ECT and PiCT for 38 hirudin samples. Thus, PiCT is a promising assay for the monitoring of anticoagulants inhibiting factor Xa and/or factor IIa.

摘要

凝血酶原酶诱导凝血时间测定法(PiCT,Pentapharm公司,瑞士巴塞尔)是一种对Xa因子和IIa因子抑制剂敏感的凝血测定法。它基于向乏血小板血浆中添加Xa因子和特异性激活V因子的蛇毒RVV-V(罗素蝰蛇毒因子V激活剂)以及磷脂。经过一段孵育时间后,向混合物中重新加入钙离子并测定凝血时间。该测定法对普通肝素(UFH)、低分子肝素(LMWHs)、重组水蛭素和阿加曲班呈现出几乎线性的剂量反应和高灵敏度。磺达肝癸钠呈现出非线性剂量反应。通过使用体外样本,得到了以下皮尔逊相关系数:120份LMWH和24份对照样本的酰胺水解抗Xa活性与PiCT之间r = 0.85;68份UFH和24份对照样本的酰胺水解抗Xa活性与PiCT之间r = 0.86;38份水蛭素样本的ECT与PiCT之间r = 0.94。因此,PiCT是一种用于监测抑制Xa因子和/或IIa因子的抗凝剂的有前景的测定法。

相似文献

1
Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors.用于测定普通肝素、低分子肝素、磺达肝癸钠和凝血酶抑制剂抗凝作用的凝血酶原酶诱导凝血时间测定法。
Am J Clin Pathol. 2008 Sep;130(3):446-54. doi: 10.1309/Q0G21Y26UR0UHQ1A.
2
Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time.通过凝血酶原诱导的凝血时间测定抗凝血酶依赖性因子Xa抑制剂
Semin Thromb Hemost. 2007 Jul;33(5):503-7. doi: 10.1055/s-2007-982081.
3
Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.体外循环期间高剂量肝素化监测——凝血酶原酶诱导凝血时间(PiCT)与两种发色底物法抗Xa因子活性测定的比较
Thromb Haemost. 2008 Feb;99(2):427-34. doi: 10.1160/TH07-04-0307.
4
Low molecular weight heparins prevent thrombin-induced thrombo-embolism in mice despite low anti-thrombin activity. Evidence that the inhibition of feed-back activation of thrombin generation confers safety advantages over direct thrombin inhibition.低分子量肝素可预防小鼠中凝血酶诱导的血栓形成,尽管其抗凝血酶活性较低。有证据表明,抑制凝血酶生成的反馈激活比直接抑制凝血酶具有安全优势。
Haematologica. 2001 Mar;86(3):297-302.
5
Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications.通过凝血酶原酶诱导凝血时间(PiCT)监测直接凝血因子Xa抑制剂和磺达肝癸钠:与凝血因子Xa活性的关系及检测方法修改的影响
Thromb Res. 2008;123(2):396-403. doi: 10.1016/j.thromres.2008.05.010. Epub 2008 Jun 24.
6
The uncalibrated prothrombinase-induced clotting time test. Equally convenient but more precise than the aPTT for monitoring of unfractionated heparin.未校准的凝血酶原酶诱导凝血时间试验。与 aPTT 相比,监测未分级肝素时同样方便,但更精确。
Hamostaseologie. 2010 Nov;30(4):212-6.
7
Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.肝素和低分子量肝素可抑制凝血酶原酶的形成,但不抑制其在血浆中的活性。
Thromb Haemost. 1994 Dec;72(6):862-8.
8
The PiCT test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.PiCT 检测在非分级肝素治疗管理中是激活部分凝血活酶时间的可靠替代方法:一项多中心研究的结果。
J Thromb Haemost. 2016 Nov;14(11):2187-2193. doi: 10.1111/jth.13489. Epub 2016 Oct 19.
9
Relative neutralization of the biological actions of sulfaminoheparosans (K5 derivatives) and heparins by protamine sulfate.硫酸鱼精蛋白对氨基硫酸化肝素(K5衍生物)和肝素生物活性的相对中和作用。
Clin Appl Thromb Hemost. 2007 Jan;13(1):52-64. doi: 10.1177/1076029606296403.
10
Monitoring Unfractionated Heparin (UFH) therapy: which Anti-Factor Xa assay is appropriate?监测普通肝素(UFH)治疗:哪种抗Xa因子测定方法合适?
Thromb Res. 2007;120(3):347-51. doi: 10.1016/j.thromres.2006.10.006. Epub 2006 Nov 21.

引用本文的文献

1
Monitoring the efficiency of reversal on anti-Xa direct oral anticoagulants using point-of-care viscoelastic testing.使用即时床旁粘弹性检测监测抗Xa直接口服抗凝剂的逆转效果。
Thromb J. 2024 Oct 8;22(1):89. doi: 10.1186/s12959-024-00659-8.
2
Point-of-Care Assessment of Direct Oral Anticoagulation in Acute Ischemic Stroke: Protocol for a Prospective Observational Diagnostic Accuracy Study.即时检测在急性缺血性脑卒中直接口服抗凝治疗中的应用:一项前瞻性观察性诊断准确性研究方案。
Thromb Haemost. 2022 Nov;122(11):1954-1962. doi: 10.1055/a-1869-7853. Epub 2022 Jun 7.
3
Monitoring of Enoxaparin during Hemodialysis Covered by Regional Citrate Anticoagulation in Acute Kidney Injury: A Prospective Cohort Study.
急性肾损伤中局部枸橼酸抗凝覆盖下血液透析期间依诺肝素的监测:一项前瞻性队列研究
J Clin Med. 2021 Sep 29;10(19):4491. doi: 10.3390/jcm10194491.
4
Monitoring of Argatroban and Lepirudin: What is the Input of Laboratory Values in "Real Life"?阿加曲班和比伐卢定的监测:“实际应用”中实验室检查结果有何作用?
Clin Appl Thromb Hemost. 2018 Mar;24(2):287-294. doi: 10.1177/1076029617699087. Epub 2017 Mar 21.
5
A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.一项关于依度沙班(一种口服 Xa 因子抑制剂)在从华法林转换后的安全性、药代动力学和药效学的随机试验。
Br J Clin Pharmacol. 2013 Apr;75(4):966-78. doi: 10.1111/j.1365-2125.2012.04409.x.
6
Monitoring of direct anticoagulants.直接凝血酶抑制剂的监测
Wien Med Wochenschr. 2011 Feb;161(3-4):58-62. doi: 10.1007/s10354-011-0876-8.